Addus HomeCare Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADUS research report →
Range $96 – $148
Price Chart
About the company
Addus HomeCare Corporation, through its various subsidiaries, offers essential personal support services across the United States. The company primarily assists seniors, individuals with chronic illnesses or disabilities, and those at risk of hospitalization or institutionalization. Its operations are structured into three primary segments: Personal Care, Hospice, and Home Health.
- CEO
- R. Dirk Allison
- IPO
- 2009
- Employees
- 50,659
- HQ
- Frisco, TX, US
Get TickerSpark's AI analysis on ADUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.28B
- P/E
- 20.14
- Fwd P/E
- 17.31
- PEG
- 0.73
- P/S
- 1.50
- P/B
- 1.90
- EV/EBITDA
- 12.82
- Div Yield
- 0.00%
- Gross Margin
- 32.32%
- Op Margin
- 10.33%
- Net Margin
- 7.39%
- ROE
- 9.81%
- ROIC
- 8.92%
Latest fiscal year · YoY change
- Revenue
- $1.42B+23.2%
- Gross Profit
- $461.87M+23.2%
- Op Income
- $138.62M
- Net Income
- $95.91M+30.3%
- EPS
- $5.19+19.9%
- OCF Growth
- -4.2%
- FCF Growth
- -6.0%
- 52W High
- $131.59
- 52W Low
- $87.95
- 50D MA
- $118.63
- 200D MA
- $107.56
- Beta
- 0.75
- RSI (14)
- 52
- Avg Volume
- 220.41K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Addus HomeCare delivered another solid quarter with double-digit profit growth, strong cash generation, and management increasingly focused on larger acquisitions and clinical expansion.· November 4, 2026
- Revenue rose 7% year over year to $387.7 million; adjusted EPS increased 17.3% to $1.83 and adjusted EBITDA rose 13.5% to $51.2 million.
- Personal care remained the largest business, with $301 million of revenue and 6.9% organic growth; hospice grew 4.1% organic and home health returned to positive organic revenue growth of 2.5%.
- Cash flow was strong at $40.9 million from operations, cash on hand was just under $100 million, and bank debt fell to $24.3 million.
- AccentCare personal care acquisition remains on track for first-quarter 2027 closing and is expected to add about $280 million in annualized revenue.
- Management expects full-year adjusted EBITDA margin to be in the 13% range and sees Q4 gross margin benefiting by about 50 to 60 basis points from hospice reimbursement and lower unemployment taxes.
Third-quarter 2026 revenue was $387.7 million, up 7% from $362.3 million a year ago. Adjusted EPS was $1.83 versus $1.56 last year, and adjusted EBITDA was $51.2 million versus $45.1 million, up 13.5%. Gross margin was 32.1% compared with 32.2% in the prior-year quarter; adjusted EBITDA margin was 13.2% versus 12.5%. Personal care revenue was $301 million, hospice revenue was $69 million, and home health revenue was $17.7 million. Cash flow from operations was $40.9 million, cash on hand was $98.5 million, and total bank debt was $24.3 million. For full-year 2026, management expects adjusted EBITDA margin to be in the 13% range; for Q4, gross margin should see a 50 to 60 basis point benefit from hospice reimbursement and lower unemployment taxes. The company also expects its fiscal 2027 hospice reimbursement rate update to provide just under 2% benefit to hospice, based on its geographic mix.
Dirk Allison framed the quarter as evidence that Addus can keep growing across all three lines of care while maintaining a strong balance sheet. He emphasized that the company is using density, scale, and selective acquisitions to expand its footprint, while also pursuing more opportunities in clinical care as pricing becomes more attractive. His tone was constructive and optimistic, especially around rate support from states, the New Mexico increase, and improving home health performance under new leadership.
Brian Poff highlighted solid operating leverage, with revenue up 7% and adjusted EBITDA up 13.5%, while gross margin stayed stable at 32.1%. He noted G&A efficiency, with G&A at 20.7% of revenue and adjusted G&A at 18.9%, down from 19.8% a year ago. On liquidity, he cited $98.5 million in cash, $650 million of revolver capacity, $617.8 million of availability, and a $40 million sequential reduction in bank debt to $24.3 million. He also said the company expects full-year tax rate in the upper 20% range, and that AccentCare is expected to be funded with cash and revolver borrowings while remaining accretive.
Analysts pressed on why PCS census was not stronger, and management said Texas and Illinois softened in September but had turned back around in October, supporting confidence in flat to slightly positive Q4 census growth. Questions on AccentCare focused on the higher private-pay mix; management said private pay is roughly 2% of Addus ADC today versus about 7% to 8% at AccentCare, and that the deal should deepen density and improve margins through G&A savings. Analysts also asked about hospice cap risk, the 80/20 rule, Medicaid work requirements, and Indiana approvals; management said no further hospice cap adjustments were expected this year, still expects movement on 80/20 by year-end, sees no current business impact from work requirements, and said the Indiana second transaction is delayed by regulatory approvals.
The quarter showed broad-based operating momentum: personal care grew, hospice remained steady, and home health turned positive for the first time in a couple of years. Management also sees more room for cash generation, rate support, and margin leverage, while the AccentCare deal should add meaningful scale and density across key markets. The balance sheet remains conservative enough to support more M&A.
PCS census growth missed management’s target in the quarter because Texas and Illinois slowed in September, and management is only expecting modest census growth rather than a return to stronger early-year rates. AccentCare will shift the mix more toward lower-margin personal care, and management said full-year EBITDA margin could come down a bit next year absent other acquisitions. Hospice still carries some regulatory and cap-related moving parts, while home health remains a small business that management is trying to rebuild rather than a major earnings driver today.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.1%
- Shares Outstanding
- 18.63M
- Float Shares
- 18.09M
of shares held by institutions
306 13F filers
Buy/sell ratio 0.19. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ADUS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.43M | ▲ 335.20K |
| Capital Research Global Investors | 1.39M | ▼ 1.29K |
| Vanguard Group Inc | 1.31M | ▲ 10.50K |
| Dimensional Fund Advisors LP | 915.83K | ▲ 80.67K |
| State Street Corp | 792.28K | ▲ 14.45K |
| Vanguard Capital Management LLC | 789.33K | ▲ 4.91K |
| Silvercrest Asset Management Group LLC | 691.25K | ▼ 37.95K |
| Wasatch Advisors LP | 627.07K | ▼ 53.85K |
| Geode Capital Management, LLC | 610.11K | ▲ 94.58K |
| Fmr LLC | 577.34K | ▲ 260.12K |
| American Century Companies Inc | 530.47K | ▼ 34.17K |
| Principal Financial Group Inc | 419.92K | ▲ 8.36K |
Held by 333 ETFs
Biggest fund positions in ADUS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Weaver Susan T | other | 1,000 |
| Nov 10, 26 | Anderson Darby | other | 6,740 |
| Nov 10, 26 | Anderson Darby | sell | 4,220 |
| Nov 10, 26 | Anderson Darby | sell | 2,520 |
| Nov 10, 26 | Anderson Darby | other | 6,740 |
| Nov 10, 26 | BLESSING CLIFF DONALD | sell | 893 |
| Nov 10, 26 | BLESSING CLIFF DONALD | sell | 2,571 |
| Nov 10, 26 | BLESSING CLIFF DONALD | sell | 35 |
| Nov 9, 26 | ALLISON R DIRK | other | 98,958 |
| Nov 9, 26 | ALLISON R DIRK | sell | 37,685 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADUS coverage
Recent articles, reports, and earnings notes.
No research on ADUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADUS report →ADUS or ELAN: Which Is the Better Value Stock Right Now?
zacks.com · Nov 20
Addus HomeCare (NASDAQ:ADUS) Stock: Insider Cliff Donald Blessing Sells 3,499 Shares
defenseworld.net · Nov 15
Addus HomeCare to Participate in 2026 Stephens Annual Investment Conference
businesswire.com · Nov 10
Addus HomeCare Corporation (NASDAQ:ADUS) Stock Now Rated “Moderate Buy” by Wall Street Brokerages
defenseworld.net · Nov 7
What Makes Addus HomeCare (ADUS) a Strong Momentum Stock: Buy Now?
zacks.com · Nov 6
Should Value Investors Buy Addus HomeCare (ADUS) Stock?
zacks.com · Nov 6
Addus HomeCare Corporation (ADUS) Hit a 52 Week High, Can the Run Continue?
zacks.com · Nov 6
Addus HomeCare Q3 Earnings Call Highlights
defenseworld.net · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.